-
CATUG Biotechnology Partners with PersonGen to Advance Global CAR-T Cell Therapies
•
China-based CATUG Biotechnology (Suzhou) Co., Ltd. has entered into a partnership with fellow Suzhou firm PersonGen BioTherapeutics (Suzhou) Co., Ltd. to collaboratively develop in vivo chimeric antigen receptor (CAR)-T cell therapies utilizing CATUG’s mRNA-lipid nanoparticle (LNP) technology for global markets. As of November 2023, a total of ten CAR-T therapies…
